Updated Jul 16, 2026
SHERMAN JEFFREY W has filed 1 SEC Form 4 filing across 1 company in the last 90 days — active on both sides. Lifetime open-market purchases: $25K. Lifetime open-market sales: $335K.
Jeffrey W. Sherman is a corporate director associated with Xeris Biopharma Holdings, Inc. and Larimar Therapeutics, Inc. He has been involved in the biopharmaceutical sector, focusing on therapies for chronic diseases.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-02 | LRMR | Larimar Therapeutics, Inc. | P — Open-market purchase | 5.0K | $5.00 | $25K |
| 2025-08-28 | XERS | Xeris Biopharma Holdings, Inc. | S — Open-market sale | 42.2K | $7.92 | $335K |
| 2025-08-28 | XERS | Xeris Biopharma Holdings, Inc. | M — Option exercise | 47.0K | $6.66 | $313K |
| 2025-06-04 | XERS | Xeris Biopharma Holdings, Inc. | A — Grant or award | 50.0K | $0.00 |
Jeffrey W. Sherman is a corporate director associated with Xeris Biopharma Holdings, Inc. and Larimar Therapeutics, Inc. He has been involved in the biopharmaceutical sector, focusing on therapies for chronic diseases.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($25K) and 1 open-market sales ($335K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live SHERMAN JEFFREY W profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.